iSpecimen Statistics
Total Valuation
iSpecimen has a market cap or net worth of $3.45 million. The enterprise value is $981,883.
Important Dates
The next estimated earnings date is Monday, November 4, 2024, before market open.
| Earnings Date | Nov 4, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
iSpecimen has 654,851 shares outstanding. The number of shares has increased by 7.82% in one year.
| Shares Outstanding | 654,851 |
| Shares Change (YoY) | +7.82% |
| Shares Change (QoQ) | +24.18% |
| Owned by Insiders (%) | 17.05% |
| Owned by Institutions (%) | 10.37% |
| Float | 543,208 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.22 |
| Forward PS | 0.52 |
| PB Ratio | 0.51 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.90, with a Debt / Equity ratio of 0.00.
| Current Ratio | 0.90 |
| Quick Ratio | 0.86 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -44.05 |
Financial Efficiency
Return on equity (ROE) is -98.03% and return on invested capital (ROIC) is -61.18%.
| Return on Equity (ROE) | -98.03% |
| Return on Assets (ROA) | -43.46% |
| Return on Capital (ROIC) | -61.18% |
| Revenue Per Employee | $198,236 |
| Profits Per Employee | -$192,362 |
| Employee Count | 53 |
| Asset Turnover | 0.71 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.09% in the last 52 weeks. The beta is 1.59, so iSpecimen's price volatility has been higher than the market average.
| Beta (5Y) | 1.59 |
| 52-Week Price Change | -45.09% |
| 50-Day Moving Average | 5.08 |
| 200-Day Moving Average | 6.41 |
| Relative Strength Index (RSI) | 54.09 |
| Average Volume (20 Days) | 600,981 |
Short Selling Information
The latest short interest is 64,238, so 9.81% of the outstanding shares have been sold short.
| Short Interest | 64,238 |
| Short Previous Month | 554,386 |
| Short % of Shares Out | 9.81% |
| Short % of Float | 11.83% |
| Short Ratio (days to cover) | 0.25 |
Income Statement
In the last 12 months, iSpecimen had revenue of $10.51 million and -$10.20 million in losses. Loss per share was -$21.17.
| Revenue | 10.51M |
| Gross Profit | 5.26M |
| Operating Income | -10.25M |
| Pretax Income | -10.20M |
| Net Income | -10.20M |
| EBITDA | -10.03M |
| EBIT | -10.25M |
| Loss Per Share | -$21.17 |
Full Income StatementBalance Sheet
The company has $2.15 million in cash and $29,130 in debt, giving a net cash position of $2.12 million or $3.24 per share.
| Cash & Cash Equivalents | 2.15M |
| Total Debt | 29,130 |
| Net Cash | 2.12M |
| Net Cash Per Share | $3.24 |
| Equity (Book Value) | 6.09M |
| Book Value Per Share | 9.30 |
| Working Capital | -577,321 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$4.90 million and capital expenditures -$14,869, giving a free cash flow of -$4.92 million.
| Operating Cash Flow | -4.90M |
| Capital Expenditures | -14,869 |
| Free Cash Flow | -4.92M |
| FCF Per Share | -$7.51 |
Full Cash Flow StatementMargins
Gross margin is 50.09%, with operating and profit margins of -97.53% and -97.04%.
| Gross Margin | 50.09% |
| Operating Margin | -97.53% |
| Pretax Margin | -97.04% |
| Profit Margin | -97.04% |
| EBITDA Margin | -95.45% |
| EBIT Margin | -97.53% |
| FCF Margin | -70.02% |